Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Accumulated Expenses: 2016-2024

Historic Accumulated Expenses for Akebia Therapeutics (AKBA) over the last 9 years, with Dec 2024 value amounting to $63.5 million.

  • Akebia Therapeutics' Accumulated Expenses rose 103.81% to $106.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $106.4 million, marking a year-over-year increase of 103.81%. This contributed to the annual value of $63.5 million for FY2024, which is 6.31% down from last year.
  • As of FY2024, Akebia Therapeutics' Accumulated Expenses stood at $63.5 million, which was down 6.31% from $67.7 million recorded in FY2023.
  • Akebia Therapeutics' 5-year Accumulated Expenses high stood at $130.6 million for FY2020, and its period low was $63.5 million during FY2024.
  • Its 3-year average for Accumulated Expenses is $69.0 million, with a median of $67.7 million in 2023.
  • In the last 5 years, Akebia Therapeutics' Accumulated Expenses climbed by 1.20% in 2020 and then plummeted by 30.49% in 2022.
  • Akebia Therapeutics' Accumulated Expenses (Yearly) stood at $130.6 million in 2020, then fell by 16.54% to $109.0 million in 2021, then slumped by 30.49% to $75.8 million in 2022, then dropped by 10.61% to $67.7 million in 2023, then fell by 6.31% to $63.5 million in 2024.